Original language | English (US) |
---|---|
Pages (from-to) | 215-216 |
Number of pages | 2 |
Journal | Neurology |
Volume | 92 |
Issue number | 5 |
DOIs | |
State | Published - Jan 29 2019 |
ASJC Scopus subject areas
- Clinical Neurology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Heterogeneity, urgency, generalizability, and enrollment : The HUGE balance in ALS trials. / Karam, Chafic; Berry, James D.
In: Neurology, Vol. 92, No. 5, 29.01.2019, p. 215-216.Research output: Contribution to journal › Editorial › peer-review
}
TY - JOUR
T1 - Heterogeneity, urgency, generalizability, and enrollment
T2 - The HUGE balance in ALS trials
AU - Karam, Chafic
AU - Berry, James D.
N1 - Funding Information: C. Karam serves on a Data Safety Monitoring Board for a Phase 2/3 Trial of Arimoclomol in Inclusion Body Myositis (IBM); has received speaker honoraria from Akcea, Alnylam, Alexion, and CSL Behring; served on the editorial boards of the Neurology Resident and Fellow section and Disputes & Debates (letters to the editor) section; and has received consulting honoraria from Akcea, Alnylam, Alexion, Biogen, Cytokinetics, Genzyme, and CSL Behring. J. Berry has served on scientific advisory boards for MT Pharma, Denali Therapeutics, Orion Corporation, Anelixis Therapeutics, and Mayo Clinic; has received travel funding from the ALS Association, Muscular Dystrophy Association, ALS One, and ALS Finding a Cure; holds a patent for MicroRNAs in neurodegenerative disorders (WO2013055865); has received research support from Voyager Therapeutics, Neuraltus Pharmaceuticals, Cytokinetics, Brainstorm Cell Therapeutics, Amylyx Pharmaceuticals, NIH, Muscular Dystrophy Association, ALS Finding a Cure, ALS Association, and ALS One; and receives licensing royalty payments for the aforementioned patent. In addition, his wife is an editorial board member of Neuro-psychopharmacology. Go to Neurology.org/N for full disclosures. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/1/29
Y1 - 2019/1/29
UR - http://www.scopus.com/inward/record.url?scp=85064443537&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064443537&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000006837
DO - 10.1212/WNL.0000000000006837
M3 - Editorial
AN - SCOPUS:85064443537
VL - 92
SP - 215
EP - 216
JO - Neurology
JF - Neurology
SN - 0028-3878
IS - 5
ER -